Nasus Pharma Ltd. Ordinary Shares (NSRX)

FairStock Score: 27/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Nasus Pharma as a speculative clinical-stage story, not a Graham-style bargain. It employs seven people and is developing intranasal emergency medicines — NS002 for severe allergic reactions and NS001 for opioid overdose. Those are serious unmet needs, but the figures offer no evidence of a durable moat or commercial traction. FairStock's calculations from the 2026-10-13 close show a $43.4 million market cap, a P/B of 10.19, and a negative P/E of -2.80. Return on equity is -316.04% and return on capital employed is -96.73%; those are not the marks of a compounding business. The Piotroski F-Score is 2/9, and the FairStock Score is 27/100. The balance sheet shows a debt-to-equity ratio of 0.01, so debt is negligible, and the Altman Z-Score of 16.24 suggests low near-term solvency risk on the supplied data. But with no revenue growth or profit growth figures available and no Lynch category because only zero years of filed results exist, there is no multi-year record to judge. The 52-week range of $1.98 to $9.50 shows how violently the market prices this binary risk. At $3.16, the stock is closer to its low, but paying about ten times book for a loss-making drug developer is not obvious value. Growth depends entirely on clinical and regulatory milestones I cannot verify in these numbers. I would need to see trial progress, cash runway, and eventually revenue before calling this anything other than a speculative venture.

In plain English: Nasus Pharma is a tiny clinical-stage drug company developing nasal sprays for emergencies such as severe allergic reactions and opioid overdose. It is not yet a proven business: it is losing money, has no meaningful sales or profit growth shown, and the stock looks expensive compared with its accounting value. The price is volatile, ranging from $1.98 to $9.50 in the past year, so this is a speculative situation rather than a stable investment.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer